

Application number
1965262

Registration number
TMA1262131

Type(s)
Standard Characters

Category
Trademark

CIPO Status
REGISTERED

TM5 status
LIVE/REGISTRATION/Issued
and Active



The trademark application has
been registered with the Office.

Filed
2019-05-28

Registered
2024-10-09

Registration Expiry Date
2034-10-09

Registered Owner
Midatech Limited
65 Innovation Drive
Milton Park
Abingdon
Oxfordshire, OX14 4RQ
UNITED KINGDOM

Agent
BORDEN LADNER GERVAIS
LLP
Bay Adelaide Centre, East
Tower
22 Adelaide St. West
TORONTO
ONTARIO M5H4E3

Documents

Index headings

MIDASOLVE
MIDA SOLVE

Goods (Nice class & Statement)

- | | |
|---|---|
| 1 | (1) Nano-particles ingredients for use in the manufacture of pharmaceuticals, medicines and cosmetics; nano-particles for use as carriers for pharmaceuticals, medicines and cosmetics; macrocyclic compounds, compositions and derivatives used as solubilising and stabilising agents for use in manufacturing pharmaceuticals, medicines and cosmetics |
| 5 | (2) Pharmaceuticals and medicines containing nano-particles for the treatment of musculoskeletal, cardiovascular, cardiopulmonary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, dermatological, and central nervous system related diseases and disorders, viral diseases and disorders, namely common cold, influenza, rabies, measles, diarrhea, hepatitis, yellow fever, polio, smallpox, AIDS, oncoviruses, and spongiform encephalopathies, metabolic diseases and disorders, namely diabetes, hypoglycemia, anemia, bulimia nervosa, anorexia, obesity, gout, osteoarthritis, and muscular dystrophy, endocrine diseases and disorders, namely growth and thyroid disorders, diabetes, osteoporosis, Addison's disease, Cushing's syndrome, Grave's disease, hyperglycemia, hypoglycemia, low testosterone, menopause, and obesity, genitourinary diseases and disorders, namely urological diseases, infertility, sexually transmitted diseases, and inflammatory pelvic diseases, neurological diseases and disorders, namely Alzheimers, Huntington's Disease, cerebral palsy, brain injury, spinal cord injury, and seizure disorders, psychiatric diseases and disorders, namely mood disorders, anxiety, cognitive disorders, schizophrenia, cognitive and bipolar disorders, and immune system diseases and disorders, namely autoimmune diseases, and immunologic deficiency syndromes; human vaccines incorporating nano-particles; veterinary vaccines incorporating nano-particles; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals and medicines to treat viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system and central nervous system related diseases and disorders |

Services (Nice class & Statement)

- | | |
|----|--|
| 40 | (1) Custom manufacture of nano-particles; custom manufacture of pharmaceuticals and medicines containing |
|----|--|

42

nano-particles; custom manufacture of nano-particle devices; custom manufacture of drug delivery agents for facilitating delivery of pharmaceuticals and medicines; custom manufacture of macrocyclic compounds, compositions and derivatives used as solubilising and stabilising agents for use in manufacturing pharmaceuticals, medicines and cosmetics
(2) Scientific research services in the field of nano-particle technology; pharmaceutical and drug research, development and discovery services; drug delivery agent research, development and discovery services; testing, efficiency and advisory services in the field of nano-particles, macro-cyclic compounds, pharmaceuticals and nano-medicine; nano-particle laboratory services

Claims

Priority Filing Date: December 06, 2018, Country or Office: UNITED KINGDOM, Application No. UK00003359021 in association with the same kind of goods and in association with the same kind of services Proposed Use in CANADA

Action History

Action	Action date	Due date	Comments
Filed	2019-05-28		
Created	2019-05-28		
Formalized	2019-05-30		
Pre-Assessment Letter Sent	2022-05-31		Goods or Services Not Acceptable
Search Recorded	2024-01-24		
Examiner's First Report	2024-01-24	2024-07-24	
Approved	2024-06-13		APPROVED BY PROGRAM EX200M1
Approval Notice Sent	2024-06-13		APPROVED BY PROGRAM EX200M1
Advertised	2024-07-10		Vol.71 Issue 3637
Registration Pending	2024-09-30		
Registration Fee Notice Sent	2024-09-30	2025-03-31	
Registered	2024-10-09	2034-10-09	